Raymond James & Associates Grifols Sa Transaction History

Raymond James & Associates

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	BUY	$5.47 - $11.38 $22,060 - $45,895	4,033 Added 36.94%	14,952 $99,000
Q4 2023 Jan 16, 2024	SELL	$7.71 - $11.56 $129,959 - $194,855	-16,856 Reduced 60.69%	10,919 $126,000
Q3 2023 Oct 24, 2023	BUY	$8.91 - $10.91 $247,475 - $303,025	27,775 New	27,775 $253,000
Q2 2022 Aug 12, 2022	BUY	$10.6 - $13.28 $324,328 - $406,328	30,597 Added 225.81%	44,147 $524,000
Q1 2022 May 11, 2022	BUY	$10.37 - $12.73 $140,513 - $172,491	13,550 New	13,550 $158,000
Q3 2021 Nov 02, 2021	SELL	$14.07 - $17.3 $679,538 - $835,538	-48,297 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$16.62 - $18.94 $466,756 - $531,910	28,084 Added 138.94%	48,297 $838,000
Q1 2021 May 14, 2021	SELL	$15.15 - $19.78 $1,242 - $1,621	-82 Reduced 0.4%	20,213 $349,000
Q4 2020 Feb 12, 2021	BUY	$16.86 - $19.67 $9,256 - $10,798	549 Added 2.78%	20,295 $374,000
Q3 2020 Nov 04, 2020	BUY	$15.4 - $20.16 $22,052 - $28,869	1,432 Added 7.82%	19,746 $343,000
Q2 2020 Jul 28, 2020	BUY	$18.24 - $21.45 $62,161 - $73,101	3,408 Added 22.86%	18,314 $334,000
Q1 2020 Apr 21, 2020	BUY	$16.28 - $25.63 $65,185 - $102,622	4,004 Added 36.73%	14,906 $300,000
Q4 2019 Feb 12, 2020	BUY	$19.57 - $23.52 $213,352 - $256,415	10,902 New	10,902 $254,000
Q1 2019 May 06, 2019	SELL	$18.01 - $20.11 $361,820 - $404,009	-20,090 Closed	0 $0
Q4 2018 Feb 11, 2019	BUY	$17.44 - $21.53 $151,204 - $186,665	8,670 Added 75.92%	20,090 $369,000
Q3 2018 Nov 14, 2018	BUY	$19.97 - $21.96 $228,057 - $250,783	11,420 New	11,420 $244,000

164

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.33B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.